Comprehensive Clinical Safety Evaluation of Oseltamivir in the Treatment of Influenza A and B in Children

A Retrospective Analysis of the Efficacy and Safety of Oseltamivir Granules and Capsules in the Treatment of Influenza A and B in Children

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017571

Enrollment

Unknown

Registered

2018-08-04

Start date

2018-09-01

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza A or B

Interventions

Influenza A group I:Oseltamivir granules

Influenza B group II:Oseltamivir granules

Influenza A group III:Oseltamivir capsules

Influenza B group IV:Oseltamivir capsules

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Children with a flu-like illness from 0 to 18 years of age (characterized with symptoms of body temperature = 38 degree C, upper respiratory symptoms and systemic symptoms) and diagnosed with influenza A or influenza B.

Exclusion criteria

Exclusion criteria: (1) Children with respiratory syncytial virus infection (fast antigen); (2) Admission time = 24h; (3) immunosuppression (drugs, transplant recipients, malignant tumors or human immunodeficiency virus infections); (4) History of allergy to acetaminophen (paracetamol); (5) Influenza treatment (within 4 weeks); (6) Participate in other clinical trials.

Design outcomes

Primary

Measure	Time frame
symptoms;	—

Countries

China

Contacts

Public ContactZhiping Li

Department of Pharmacy, Children's Hospital of Fudan University

zhipinglifudan@yeah.net+86 18017590744

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026